Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50,422 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Tumor Clear all

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions: Rociletinib; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 39
States / cities: Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more

Conditions: Soft Tissue Sarcoma
Interventions: Hypofractionated Radiotherapy; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions: PF-06463922, Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 32
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more

Conditions: Lung Neoplasms
Interventions: Breath Collection Apparatus; Device
Lead sponsor: Menssana Research, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Newark, Delaware • Orlando, Florida • New York, New York + 1 more

Conditions: Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Interventions: Not listed
Lead sponsor: Luventix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Encinitas, California • Santa Monica, California • Walnut Creek, California

Conditions: Neuroendocrine Tumors
Interventions: Satoreotide tetraxetan, Amino acid solution, Antiemetic; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Berkeley, California • Duarte, California • Los Angeles, California + 22 more

Conditions: Adenocarcinoma, Colon Cancer
Interventions: XELOX, XELIRI, Bevacizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 12
States / cities: Deerfield Beach, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 8 more

Conditions: Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
Interventions: Laboratory Biomarker Analysis, Natural Killer Cell Therapy; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
Interventions: Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI); Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York

Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: vorinostat, conventional surgery; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Barrett's Esophagus, Intraepithelial Neoplasia
Interventions: proflavine; Drug
Lead sponsor: Anandasabapathy, Sharmila, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastro-Intestinal Cancer
Interventions: 5-FU, Leucovorin, Irinotecan, Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Dallas, Texas • Temple, Texas

Conditions: Pancreas Cancer
Interventions: Plerixafor; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate, Cancer, Hormonal Cycling
Interventions: GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Wilms Tumor, Sarcoma, Spindle Cell, Sarcoma Rhabdoid, Childhood Sarcoma of Soft Tissue
Interventions: Not listed
Lead sponsor: Florida International University; Other
Eligibility: Up to 21 Years
Enrollment: 14 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult, Acute Myelogenous Leukemia, High Risk Myelodysplasia
Interventions: APTO-253; Drug
Lead sponsor: Aptose Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 13
States / cities: Tucson, Arizona • La Jolla, California • Orange, California + 10 more

Conditions: Lung Cancer
Interventions: cytology specimen collection procedure, physiologic testing, annual screening, study of high risk factors; Other · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years and older
Enrollment: 3,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Breast Cancer
Interventions: KIBUR MICRODEVICE, anthracycline and taxane based chemotherapy; Device · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Thymoma, Thymic Carcinoma
Interventions: Premetrexed (Alimta); Drug
Lead sponsor: Patrick Joseph Loehrer Sr.; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions: Gemcitabine, Bevacizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Fresno, California • San Diego, California + 13 more

Conditions: Colorectal Cancer Control and Prevention
Interventions: single GPT generated message, AI Chatbot, Expert-Written Patient Materials; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 75 Years
Enrollment: 915 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: JNJ-75229414, Bridging Therapy; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more

Search by objective public record fields.

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Breath Test for Early Detection of Lung Cancer

Urine Metabolites in the Diagnosis of Disease

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Drug Sensitivity and Mutation Profiling

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Sputum Cytology in Screening Heavy Smokers For Lung Cancer

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Effect of Static vs. Conversational AI-Generated Messages on Colorectal Cancer Screening Intent: a Randomized Controlled Trial

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants